Kairos Pharma has signed a binding term sheet agreement to acquire exclusive worldwide rights to CL-273 from Celyn Therapeutics.[1][3] CL-273 is an investigational, reversible, wild-type-sparing pan-EGFR mal molecule inhibitor designed using an AI platform for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC).[1][2] The drug covers a wide spectrum of classical EGFR mutations, including Exon 19 and 21 deletions, Exon 20 insertions, atypical mutations and resistant variants.[1] It offers a 4-5-fold wider therapeutic window due to specificity against wild-type EGFR, which improves safety and tolerability.[1] It has high permeability to the brain and lungs and has successfully passed GLP toxicology studies.[1] The program is in the pre-IND stage, with a planned start of human clinical trials in 2026.[1][2] The deal also includes CL-741, a Phase 1-ready oral c-MET inhibitor, for combination therapy against resistance in NSCLC.[4][5] The market for EGFR-mutant NSCLC is estimated at $16.2 billion in 2026.[3][5]